Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
) u$ S W d* ?0 | d. }( E* n3 a5 m4 d" A1 K
/ i$ \& W' Q9 ]: l" d, x" o
Sub-category:8 N2 o+ { E5 o! v( k: S: @
Molecular Targets
2 r9 }4 n3 u6 N0 Q) _' x& _2 R, W! ?0 v" f
9 E9 e# S* A$ Q5 g7 y9 A$ A( d5 a$ ECategory:
6 }/ A. G$ U% T+ J* S7 BTumor Biology
H" g4 m' U9 r& k* J8 T- D6 d7 U- Z$ v9 |+ U* m; d
% T( b7 I/ M6 K: e
Meeting:- q! A6 P! k7 }% g9 p9 ]
2011 ASCO Annual Meeting
4 q2 d5 U$ I' C7 [" n6 {. t, I$ e) E
8 `5 l [0 \$ g( C9 V' ]' h
Session Type and Session Title: ]+ `% D: f) K$ V2 \5 a; ^
Poster Discussion Session, Tumor Biology
! K" Y* t* k2 h* c% ~ B+ ^- I( U- L/ q
# }! i% y! z% v# Q
Abstract No:
* P% K0 m/ t m w# F10517
1 z; S! A9 e; Z! H" c8 X6 z/ \# \! @# ?+ u( u: }! a, e. s
( s6 t/ M4 \' k. U9 {Citation:6 q9 U/ ?5 y# h6 j& A* L9 k
J Clin Oncol 29: 2011 (suppl; abstr 10517)
. B! z6 T* L% T! F1 a% _" h% U. P m0 O" ]2 Z6 I
3 X v: d1 y; J7 m2 cAuthor(s):; H$ Z: D$ U) q: n, Y
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
4 o$ ]3 ~; Q* P4 _; T( P
( O- y$ ]9 G# b6 I
( G( b$ z' }4 B) H `; W
3 |, U) X K0 J; \" |# E4 rAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.* c2 \9 L3 N$ i. \0 V
( w2 k2 Q7 Q+ p+ o4 y VAbstract Disclosures+ T( a k4 P7 i9 ~4 S2 G
# ]2 T$ H6 {3 D0 r1 t% h
Abstract:$ Z* @2 E6 f/ U
0 g* j" |1 f- e) O3 L) C- S" L' d" X# m; q
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
$ G4 s" b$ x1 n% n; ?, T
- f( @! M7 f+ ]( D: _+ G
6 ?( h! @- P+ \+ A: g7 x |
显身卡
